Duodenal Ulcer and Eradication of Helicobacter pylori in a Developing Country An 18-Month Follow-up Study

References

• Kumar N, Vig J C, Karol A, Anand B S. Controlled therapeutic trial to determine the optimum dose of antacids in duodenal ulcer. Gut 1984; 25: 1199–202
   PubMed Web of Science ®Google Scholar
• Bardhan K D, Bianchi Porro G, Bose K, et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Gastroenterol 1986; 8: 408–13
   Google Scholar
• Freston J W. Overview of medical therapy of peptic ulcer disease. Gastroenterol Clin N Am 1990; 19: 121–40
   PubMed Web of Science ®Google Scholar
• Boyd E JS, Wilson J A, Wormsley K G. Safety of ranitidine maintenance treatment for duodenal ulcer. Scand J Gastroenterol 1984; 19: 394–400
   PubMed Web of Science ®Google Scholar
• Marshall B J, Warren J R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311–5
   PubMed Web of Science ®Google Scholar
• Goodwin C S, Armstrong J A, Marshall B J. Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 1986; 39: 353–65
   PubMed Web of Science ®Google Scholar
• Blaser M J. Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease. Gastroenterology 1987; 93: 371–83
   PubMed Web of Science ®Google Scholar
• Rauws E AJ, Langenberg W, Houthoff H J, Zanen H C, Tytgat G NJ. Campylobacter pyloridis associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 94: 33–40
   PubMedGoogle Scholar
• Coelho L GV, Das S S, Payne A, Karim Q N, Baron J H, Walker M M. Campylobacter pylori in the esophagus, antrum and duodenum. A histological and microbiological study. Dig Dis Sci 1989; 34: 445–8
   PubMedGoogle Scholar
• Sidney 1990. J Gastroenterol Hepatol 1991; 6(3)207–52, Working Party Report to the World Congress of Gastroenterology
   PubMedGoogle Scholar
• Coghlan J G, Humphreis H, Dooley C, et al. Campylobacter pylori and recurrence of duodenal ulcers. A 12 month follow-up study. Lancet 1987; 2: 1109–11
   PubMed Web of Science ®Google Scholar
• Marshall B J, Warren J R, Blincow E D, et al. Prospective doubleblind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2: 1427–41
   PubMedGoogle Scholar
• Borody T J, Cole P, Nooman S, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 1989; 151: 431–5
   PubMed Web of Science ®Google Scholar
• Rauws E AJ, Tytgat G NJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 335: 1233–5
   PubMed Web of Science ®Google Scholar
• George L L, Borody T J, Andrews P, et al. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust 1990; 153: 145–9
   PubMed Web of Science ®Google Scholar
• Coelho L GV, Passos M CF, Chausson Y, Castro L P. Five-day bismuth-free triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse. Am J Gastroenterol 1991; 86: 971–5
   PubMedGoogle Scholar
• Coelho L GV, Chausson Y, Passos M CF, et al. Test respiratoire a l'uree marquée au carbone-14 pour le diagnostic de la colonization gastrique par Helicobacter pylori. Gastroenterol Clin Biol 1990; 14: 801–5
   PubMedGoogle Scholar
• Axon A TR. Helicobacter pylori therapy: effect on peptic ulcer disease. J Gastroenterol Hepatol 1991; 6: 131–7
   PubMed Web of Science ®Google Scholar
• Graham D Y, Borsch G MA. The who's and when's of therapy for Helicobacter pylori. Am J Gastroenterol 1991; 85: 1552–5
   Google Scholar
• Goodwin C S, Marshall B J, Blincow E D, et al. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 1988; 41: 207–10
   PubMed Web of Science ®Google Scholar
• Becx M CMJ, Janssen A JHM, Clasener H AL, et al. Metroni-dazole-resistant Helicobacter pylori. Lancet 1990; 1: 539–40
   Google Scholar
• Glupczynski Y, Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol 1991; 85: 1545–51
   Google Scholar
• Glupczynski Y, Burette A, De Koster A, et al. Epidemiological factors associated with metronidazol resistance in Helicobacter pylori. Lancet 1990; 1: 976–7
   Google Scholar
• Zhao H Y, Li G, Guo J, et al. Furazolidone in peptic ulcer. Lancet 1985; 98: 616–7
   Google Scholar
• Zheng Z T, Wang Z Y, Chu Y A, et al. A double-blind shortterm clinical trial of furazolidone on peptic ulcers. Chin Med J 1985; 98: 616–7
   PubMedGoogle Scholar
• Coelho L GV, Queiroz D MM, Barbosa A JA, et al. Furazolidone x cimetidine in duodenal ulcer C. pylori positive patients. Gastroenterology 1989; 96: A91
   Google Scholar
• Zheng Z T, Xing L P. Effect of furazolidone on gut catecholamine in cysteamine-induced duodenal ulcer in the rat. Scand J Gastroenterol 1988; 23: 1020–4
   PubMed Web of Science ®Google Scholar
• Coelho L GV, Passos M CF, Queiroz D MM, et al. Five days triple therapy and 15 days double therapy on C. pylori eradication. Klin Wochenschr 1989; 67: 11, Suppl XVIII
   PubMedGoogle Scholar
• Graham D Y. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol 1991; 6: 105–13
   PubMed Web of Science ®Google Scholar
• Lian J X, Carrick J, Lee A, Daskalopoulos G. Long-term recurrence of Helicobacter pylori infection after successful eradication with ‘triple therapy’. Gastroenterology 1991; 100: A110
   Google Scholar
• Wyatt J I, Rathbone B J, Heatley R V. Local immune response to gastric Campylobacter in non-ulcer dyspepsia. J Clin Pathol 1986; 39: 863–70
   PubMed Web of Science ®Google Scholar